Sign inJoin waitlistJoin the waitlist

EB

Elizabeth Buchbinder

Explains How Skin Color Influences Melanoma Risk. · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present

Medical Oncology
2007–2009
Internal Medicine
2004–2007
Tufts University School of Medicine
2000–2004

Research

An immunogenic personal neoantigen vaccine for patients with melanoma
Nature · 2017 · 2,312 citations
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Review · American Journal of Clinical Oncology · 2016 · First of 2 authors · Corresponding · 1,901 citations
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Cell · 2018 · 1,126 citations

Stephen Hodi
31 papers
Patrick Ott
29 papers
Ryan Sullivan
26 papers · 2 as a fellow
Rizwan Haq
16 papers
Douglas Johnson
12 papers
David McDermott
10 papers
DL
Donald Lawrence
10 papers
Justine Cohen
10 papers
Sapna Patel
10 papers
Jeffrey Sosman
8 papers
John Kirkwood
8 papers
Antoni Ribas
7 papers

Clinical trials

Sargramostim (GM-CSF) + PD-1
Principal investigator · Withdrawn · Phase 2
Dana-Farber Cancer Institute
2021–2025
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Principal investigator · Withdrawn · Phase 2
Dana-Farber Cancer Institute
2019
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Principal investigator · Completed · Phase 1, Phase 2
Dana-Farber Cancer Institute
2018–2023
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Principal investigator · Completed · Phase 1, Phase 2
Dana-Farber Cancer Institute
2017–2020